<DOC>
	<DOC>NCT01944618</DOC>
	<brief_summary>The study purpose is to assess adverse events in patients with Type 2 diabetes who have newly been prescribed Forxiga for the management of glycemic control</brief_summary>
	<brief_title>forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)</brief_title>
	<detailed_description>Observational Model: Other: A post-marketing evaluation of the safety of Forxiga through an observational prescription adverse event monitoring program (registry-based monitoring program) is warranted to assess real-world incidence of adverse events in routine clinical practice</detailed_description>
	<criteria>Patients with Type 2 Diabetes who are: Prescribed Forxiga for glycaemic management AND Who have the ability to provide informed consent Patients with whom use of Forxiga is contraindicated: Patients with Type 1 Diabetes Patients with moderate to severe renal impairment [Creatinine clearance (CrCl) &lt;60 mL/min or estimated glomerular filtration rate (eGFR) &lt;60mL/min/1.73mÂ²] Additional exclusion criteria: Age &gt;75 years Concomitant use of loop diuretics or pioglitazone Patients who are currently on another SGLT2 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>